Mumbai, Philippines, September 07, 2022: Global pharma major, Lupin Limited (Lupin) and DKSH, a leading partner for healthcare companies seeking to grow their business in Asia and beyond, announced today that they have signed an exclusive license and supply agreement to commercialize five of Alvotech’s proposed biosimilars in the Philippines. The biosimilars planned under this agreement include biosimilar Prolia® (denosumab 60mg/ml), Xgeva® (denosumab 70 mg/ml), Simponi® (golimumab), and Eylea® (aflibercept) as well as two undisclosed proposed biosimilars for immunology and oncology.

According to the agreement, Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for distribution and commercialization of the biosimilars once approved.

These reference products are used to treat disorders relating to bone disease, oncology, immunology and ophthalmology. This agreement enhances Multicare’s oncology, rheumatology, gastroenterology and ophthalmology, portfolio, which currently consists of three biosimilar candidates and over 50 generic medicines.

“We are pleased to announce the addition of five new biosimilar candidates to our portfolio, which will provide patients in Philippines with effective, high-quality and affordable treatment options,” said Gabriel Georgy, Regional Head Southeast Asia, Lupin.

Peter Dolinsky, Vice President Own Brands, Asia Pacific at DKSH added, “We are delighted to partner with Lupin and bring these important therapeutic offerings to patients in the Philippines. This partnership is in line with our purpose of enriching people’s lives, and we are proud to be working with a strong local partner to make this happen.”

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 8.7% of its revenue in research and development in FY22.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.
Follow us on Twitter: https://twitter.com/LupinGlobal
LinkedIn: https://www.linkedin.com/company/lupin
Facebook: http://www.facebook.com/LupinWorld/

About DKSH

DKSH’s purpose is to enrich people’s lives. For more than 150 years, we have been delivering growth for companies in Asia and beyond across our Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, we offer sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 33,100 specialists, generating net sales of CHF 11.1 billion in 2021. The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical devices. With around 7,920 specialists, the Business Unit generated net sales of CHF 5.6 billion in 2021. www.dksh.com/hec

About Alvotech

Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities.

Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea).

Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com. 

For further information, please contact –

Shweta Munjal, Lupin
Vice President & Global Head – Corporate Communications
Email: shwetamunjal@lupin.com

Sheena Flannery, DKSH
Director Group Marketing
Email: sheena.flannery@dksh.com